218 results about "Sarcoma" patented technology

The invention provides compounds that degrade the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein including mutant forms via the ubiquitination of the KRAS protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

The invention provides compounds that degrade the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein including mutant forms via the ubiquitination of the KRAS protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

The invention belongs to the field of biological detection, and particularly relates to an ewing sarcoma detection primer group, a kit and application thereof. The Ewing sarcoma detection primer group comprises a primer group A and a primer group B, and totally has 17 primer sequences. The primer group is designed, Ewing sarcoma characteristic variation genes are detected through multiple fluorescent PCR and a high-resolution capillary electrophoresis apparatus, 24 variation types fused by 7 types of genes can be detected at a time, the lowest detection limit is 10 copies, and the shortest detection time is 240 minutes. The detection result of the primer group disclosed by the invention can pass Sanger sequencing verification and is completely consistent with the morphological diagnosis result, the methodological consistency reaches 100%, and a sensitive and efficient Ewing sarcoma genetic variation detection method is provided.

It is an object of the present invention to provide drugs that bind specifically to FAPα, are effective in the treatment and diagnosis of tumors or cancers expressing FAPα, for example, in the treatment and diagnosis of solid cancers such as pancreatic cancer, sarcoma, esophageal cancer, lung cancer, breast cancer, prostate cancer, head and neck cancer, ovarian cancer, colon cancer, neuroendocrine tumor, thyroid cancer, uterine cancer, liver cancer and the like (particularly, pancreatic cancer), and have a lower risk of prolonged side effects. The present invention provides a conjugate comprising a radioactive moiety comprising an aryl group substituted with a radionuclide selected from 211At, 210At, 131I, 125I, 124I, 123I, 77Br and 76Br, and a bioactive moiety having an affinity for fibroblast activation protein α (FAPα).

Provided herein are kinase fusion nucleic acid molecules and polypeptides, methods related to detecting kinase fusion nucleic acid molecules and polypeptides in cancer, as well as methods of treatment and uses related thereto. Detection of a kinase fusion nucleic acid molecule or the fusion polypeptide encoded by the fusion nucleic acid molecule can be used to identify individuals that may benefit from treatment with an anti-cancer therapy.

The invention discloses an application of the number of neutrophils in predicting the curative effect of oncolytic viruses in treating tumors. In the application, the neutrophile granulocyte number level in the blood of a tumor patient is closely associated with the tumor treatment effect, and the applicable tumor syndromes are common, including melanoma, colorectal cancer, esophageal cancer, head and neck tumors, gastric cancer, biliary tract system tumors, sarcoma and other tumors. In the application, the critical value of the number of neutrophils for predicting the tumor treatment effect is 2 * 10 < 9 >-5.5 * 10 < 9 > / L, and the most preferable critical value is 4.0 * 10 < 9 > / L; the curative effect of OH2 single-drug treatment on tumor patients with the neutrophil number level below a critical value is better than that of tumor patients with the neutrophil number level above the critical value.

The invention discloses a novel polypeptide, a polypeptide derivative and application thereof, and belongs to the technical field of biological medicine. The invention specifically relates to a specific sequence, a discovery process, a specific anti-tumor type, a long-acting modification mode and application of the novel polypeptide. The tumors comprise one or more of brain glioma, neuroblastoma, head and neck cancer, esophagus cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestinal cancer, ileocecum cancer, stomach cancer, bladder cancer, pancreatic cancer, prostate cancer, bile duct cancer, melanoma, sarcoma, myeloma, lymphoma and leukemia; the compound has the specific effect of inhibiting proliferation and / or metastasis of tumor cells, is wide in treatment spectrum and has important treatment value in various tumors.

The invention discloses a method for performing sarcoma high-frequency neoantigen function verification based on tumor organoids, and the method for performing sarcoma high-frequency neoantigen function verification based on tumor organoids comprises the following steps: after separating PBMC, enriching CD8 + T cells, and stimulating the CD8 + T cells by using DC loaded with candidate neoantigen polypeptide to obtain neoantigen specific CTL; new antigen-specific CTL is tested through the kit, secretion of IFN-gamma is detected, and antigen-specific CTL with positive reaction is screened out; the method comprises the following steps: selecting a candidate new antigen capable of specifically stimulating CTL to generate an IFN-gamma positive reaction according to an experiment result of secreting IFN-gamma by the CTL, establishing a tumor organoid-CTL cell co-culture system, setting PBMC primary T cells of a patient which are not stimulated by DC loaded with the candidate new antigen as a control group, and measuring organoid light microscope radiography and tumor cell death conditions. The function of the sarcoma high-frequency neoantigen is evaluated based on tumor organs.

Methods of treating, suppressing, or reducing the severity of a liver cancer in a subject are described herein. The disclosed methods involve administering a therapeutically effective amount of a composition including safranal or its pharmaceutically acceptable pro-drug, and a pharmaceutically acceptable carrier to the subject. The disclosed methods may be used to treat, suppress, or reduce the severity of various liver cancers, including hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocarcinoma, angiosarcoma, a metastatic liver cancer, and combinations thereof.

The invention discloses a pelvic soft osteosarcoma MRI (Magnetic Resonance Imaging) segmentation method based on edge-guided multi-scale fusion. The method comprises the following steps: firstly, acquiring an MRI image of a patient with soft osteosarcoma of pelvis, and preprocessing the image; and then, constructing a pelvic soft osteosarcoma MRI segmentation network model, namely an EMU-Net segmentation network, based on edge-guided multi-scale fusion. And training the network by using the preprocessed training data, inputting a pelvic soft osteosarcoma MRI image to be segmented into the trained network, outputting a corresponding segmentation probability graph, and obtaining a final tumor segmentation mask by setting a threshold value. The method not only effectively overcomes the clinical segmentation bottleneck, but also realizes full-automatic and high-efficiency precise segmentation by means of an end-to-end deep learning architecture, and has remarkable advantages in the aspects of precision and robustness.

The invention discloses application of neutrophile granulocyte number level in prediction of tumor treatment effect. Through verification of the embodiment of the invention, the number level of neutrophils in blood of a tumor patient before treatment is closely associated with the curative effect of tumor treatment, especially OH2 treatment, and the applicable tumor adaptation diseases are common; comprising at least one of melanoma, esophageal cancer, right breast invasive ductal cancer, intestinal cancer, head and neck tumor, gastric cancer, ovarian cancer, biliary system tumor, left foot back squamous cell carcinoma, sarcoma and osteosarcoma, lung cancer, thymosquamous cell carcinoma and brain glioma. In the application disclosed by the invention, the threshold value of the number of neutrophils for predicting the tumor treatment effect is 3.5 * 10 < 9 > / L; the treatment is predicted to be effective when the number of sexual granulocytes in a tumor patient is below 3.5 * 109 / L before the tumor patient is treated, and the treatment is predicted to be ineffective or invalid when the number of sexual granulocytes in the tumor patient is higher than 3.5 * 109 / L. The application method is simple, low in cost and good in stability, and can become a potential prediction means for clinicians.

The invention relates to a bicyclic heterocyclic compound as well as a preparation method and medical application thereof. In particular, the present invention relates to a compound represented by general formula (IA), a preparation method thereof, a pharmaceutical composition containing the compound, and a use thereof as a PRMT5 inhibitor. The compound and the pharmaceutical composition containing the compound can be used for treating and / or preventing PRMT5 activity related diseases, such as non-small cell lung cancer, mesothelial tissue tumor, nerve fiber sarcoma, pancreatic cancer, solid tumor and the like. Wherein the definition of each group in the general formula (IA) is the same as that in the specification. # imgabs0 #

The present disclosure features methods for identifying pateints having a hyperproliferative disease, disorder, or condition responsive to phosphodiesterase 3 (PDE3) and schlafen family member 12 (SLFN12) complex formation. The hyperproliferative disease, disorder, or condition may be cancer in a patient including glioblastoma, melanoma, ovarian cancer, cervical cancer, sarcoma, or hematopoietic cancers, such as acute myeloid leukemia. Those responsive diseases, disorders, or conditions may be identified using the biomarker AIP and / or TRRAP in combination with those biomarkers pertinent to phosphodieseterase 3 and schlafen family member 12 complexes which may be formed by PDE3 modulation with certain active compounds. Expression of combinations of these biomarkers have been shown to correlate with active compound (e.g., PDE3 modulator, PDE3A modulator, PDE3B modulator) sensitivity.

Disclosed are a novel polypeptide, a polypeptide derivative and the use thereof, which belong to the technical field of biomedicine. The present application specifically relates to a specific sequence, a discovery process, specific types of tumors to be resisted, a long-acting modification method and the use of the novel polypeptide, wherein the tumors include one or more of glioma, neuroblastoma, head and neck cancer, esophageal cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestine cancer, ileocecal cancer, gastric cancer, bladder cancer, pancreatic cancer, prostate cancer, cholangiocarcinoma, melanoma, sarcoma, myeloma, lymphoma and leukemia; and the specific use comprises the inhibition of the proliferation and / or metastasis of the above-mentioned tumor cells. The novel polypeptide has a wide therapeutic spectrum and important therapeutic value against various tumors.

The present invention relates to inhibitors of Kirsteen rat sarcoma virus (KRAS), and more particularly to compounds of formula (I), as well as compositions comprising formula (I) and methods of using compounds of formula (I) to treat or prevent diseases, disorders or medical conditions mediated by KRAS, in particular KRAS mutant G12C. # imgabs0 #

The invention belongs to application of PLOD2 as a biomarker in preparation of a product for detecting sarcoma-like renal cell carcinoma, and belongs to the field of biomedicine. The invention finds that PLOD2 is a molecular marker of sarcoma-like renal cell carcinoma, the expression of PLOD2 in sarcoma-like renal cell carcinoma is significantly higher than that in non-sarcoma-like renal cell carcinoma and normal kidney tissue, and in the same sarcoma-like renal cell carcinoma tissue, the expression of PLOD2 in a sarcoma-like component is significantly higher than that in an adjacent epithelioid renal cell carcinoma component and paracancerous normal kidney tissue. Therefore, PLOD2 can be used as an auxiliary diagnosis molecular marker of sarcoma-like renal cell carcinoma, and has important clinical application value for improving the clinical diagnosis level of the disease.

Methods and compositions are described herein that are useful to treat pathological mutation in the fused in sarcoma (FUS) gene. A number of FUS mutations are correlated with neurodegenerative conditions such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The methods and compositions can target and reduce or eliminate such FUS mutations.

Described herein are Kirsten rat sarcoma viral oncogene homologue (KRAS) inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a KRAS associated disease or disorder.

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.

The application relates to a sarcoma fusion gene nanopore sequencing primer set and application thereof, wherein the primer set comprises five pairs of specific primers (Primer 1-5) with fixed sequences, each primer follows the design principle of 18-25 bp in length, 40%-60% in GC content and strict matching of a target sequence at a 3' end, and the length of an amplification product is 300-800 bp, which is suitable for nanopore sequencing. Through qPCR verification, the primer set has single-peak melting curves, close-to-100% amplification efficiency, strong specificity and excellent amplification performance.

The present disclosure relates, inter alia, to the combination therapy of an oncolytic adenovirus for the treatment of retinoblastoma, Ewing's sarcoma or neuroblastoma with a topoisomerase I inhibitor or a prodrug thereof, such as topotecan or SN-38, or a prodrug of a topoisomerase inhibitor, such as irinotecan.

A multi-target kinase inhibitor is shown in formula (I), in which R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit the enzymatic activities of RET, VEGFR3 and PDGFRA, and can effectively treat diseases that are regulated and controlled by multi-target kinases and are related to abnormal signal transduction pathways of the multi-target kinases, including cancers of breast, respiratory tract, brain, reproductive organ, digestive tract, urinary tract, eye, liver, skin, head and / or neck and distant metastatic cancers thereof, and lymphoma, sarcoma, leukemia and the like. The active ingredients of the pharmaceutical composition of the present invention comprise a multi-target kinase inhibitor, which accounts for 1-50 wt % of the composition.

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

The invention discloses an application of an OH2 oncolytic virus combined with a PD-1 inhibitor in preparation of an antitumor drug. The OH2 oncolytic virus and the PD-1 inhibitor are jointly applied to tumor treatment, and through the synergistic effect of the OH2 oncolytic virus and the PD-1 inhibitor, the anti-tumor immune response is enhanced, and the treatment effect is improved. According to the combined treatment scheme, tumor cells can be directly killed, recurrence and metastasis of tumors can be inhibited by activating systemic immune response, and a new treatment choice is provided for tumor patients. In the application, the neutrophile granulocyte number level in the blood of a tumor patient is closely associated with the treatment effect of the anti-tumor medicine, the anti-tumor medicine can be used for evaluating the treatment effect, and the anti-tumor medicine is suitable for common tumor adaptations including colorectal cancer, esophageal cancer, head and neck tumor, gastric cancer, biliary tract system tumor, sarcoma, melanoma and other tumors.

The present invention relates to aptamers that specifically bind to the extra-cellular domain of alpha7 / beta1 integrin dimers, conjugates or particles comprising said aptamers, in muscles cells such as skeletal muscle fibres and satellite cells, or in cells aberrantly expressing said domain e.g. tumour cells such as rhabdomyosarcoma (muscle-derived tumours), or glioblastoma cancer stem cells, as well as conjugates comprising said aptamers, therapeutic or diagnostic compositions comprising said conjugates or said aptamers, and their use as a medicament and in diagnostic methods.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, prostate, lymphatic system, liver, ovary, or cervix. Additional examples of cancers for which the disclosed compounds and compositions can be useful include, but are not limited to, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinomas, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and / or ADC) to an ENPP1 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and / or ADCs) that bind to an ENPP1 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer (e.g., one or more sarcomas) are provided.

The present disclosure relates to 4'-thio-nucleotides and nucleoside compounds for the treatment of various cancers, such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative tumors and plasma cell neoplasms (myeloma). The abstract is intended to be a scanning tool for the purpose of searching in a specific field and is not intended to limit the present invention.

The present invention relates to new aptamers against EphA2 (ephrin type-A receptor 2), chemically modified versions thereof and / or complexes comprising any thereof, as well as compositions comprising any of these. It further pertains to their use in a method ofEphA2 detection or quantification, or alternatively in a method comprising EphA2 detection or quantification, such as for the screening, diagnosis, prognosis, or monitoring of a EphA2-related disease. It further pertains to the use of the nucleic acid aptamer, complex or composition in a prophylactic and / or therapeutic method for the treatment of a EphA2-related disease, such as EphA2 expressing cancers, including Ewing sarcoma, and to related kits.